Primary Objective. Assess changes in PTSD symptoms in participants receiving the full dose of MDMA compared to the low dose as measured by Global CAPS scores at baseline and the primary endpoint, one month after the second experimental session.
Appears in 1 contract
Sources: Sponsor Agreement
Primary Objective. Assess changes in PTSD symptoms in participants subjects receiving the full dose of MDMA compared to the low comparator dose as measured by Global CAPS scores at baseline and the primary endpoint, one month after the second experimental session.
Appears in 1 contract
Sources: Sponsor Agreement